Markets Face Weeks of Uncertainty in Wait for Virus Answers
The fate of global markets now depends at least in part on laboratories around the world probing the omicron Covid-19 strain.
(Bloomberg) -- The fate of global markets now depends at least in part on laboratories around the world probing the omicron Covid-19 strain, potentially leaving investors with weeks of uncertainty in the wait for answers.
The variant detected in Africa is described as highly worrying and international travel bans are proliferating. Scientists are analyzing whether it can evade inoculations and the severity of illness it causes. Vaccine maker BioNTech SE expects the first data within two weeks, initial findings that will help determine if a passing scare or bigger hit to global economic reopening looms.
Reports of mild omicron cases so far brought some stability to markets Monday after a plunge in stocks and crude oil and a spike in volatility on Friday. But definitive data are scarce: Citigroup Inc. strategists including Jamie Fahy and Yasmin Younes estimated the window for more clarity may be two to eight weeks, and cautioned about investors cutting back on leveraged positions.
“At a minimum, volatility will be higher the next two weeks,” said Peter Berezin, chief global strategist at BCA Research Inc. Stocks could drop further but a slide of more than 10% is a buying opportunity, he added.
Oil rebounded about 4% on Monday to scale $71 a barrel but remained some $7 shy of the price before Friday’s omicron fright. The 10-year U.S. Treasury yield pushed higher but was also below Nov. 24 levels. Futures suggested Europe and the U.S. will help global shares climb from around a six-week low.
Traders have cut back bets on tighter monetary policy to fight inflation -- which had been the dominant theme amid expectations that the worst of the pandemic was over. Just what omicron means for growth and inflation, however, remains foggy.
“Inflation may have a brief respite by lower energy prices, but lockdowns add to supply constraints while U.S. consumer demand is unabated,” said Ben Emons, global macro strategist with Medley Global Advisors LLC.
Amid the uncertainty, investors sitting on solid year-to-date gains as Christmas nears -- 22% for the S&P 500 -- may be tempted to bank some profits. Another possibility is a preference for the work- and stay-at-home trade until more data surfaces, said Ryan Jacob of Jacob Asset Management.
Major portfolio changes likely aren’t necessary assuming existing vaccines remain effective and that omicron isn’t more malicious than other strains, Goldman Sachs Group Inc. wrote in a note.
But short-term portfolio hedges may be appropriate “given the time of the year and liquidity as well as policy risks in December,” according to the note, which gave call options on 10-year Treasury futures as among the hedges to consider.
Past virus scares ended up being a chance to load up on equities, and the question is if the same narrative is unfolding again.
The challenge here is that omicron likely wasn’t the only factor at play in the equity swoon, according to Peter Tchir, head of macro strategy at Academy Securities Inc. The other variables include less dovish central bankers and the fact that stock prices looked stretched on some measures.
“I wouldn’t be surprised to get a bounce as we decide omicron is manageable, but I would fade that bounce, as it isn’t all that is going on here,” Tchir said.
©2021 Bloomberg L.P.